US · GNLX
Genelux Corporation
- Sector
- Healthcare · Biotechnology
- Headquarters
- Westlake Village, CA 91361
- Website
- genelux.com
Price · as of 2024-12-31
$2.74
Market cap 112.1M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $31.96 | +1,066.42% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $78.76 | +2,774.45% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | $22.32 | ||||
| 2023 | $6.36 | $40.35 | $0.00 | $0.00 | $99.61 |
| 2024 | $4.20 | $31.96 | $0.00 | $0.00 | $78.76 |
AI valuation
Our deep-learning model estimates Genelux Corporation's (GNLX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $31.96
- Current price
- $2.74
- AI upside
- +1,066.42%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
$78.76
+2,774.45% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GNLX | Genelux Corporation | $2.74 | 112.1M | +1,066% | — | — | +2,774% | -4.42 | 5.03 | 16511.63 | -3.56 | — | 5.03 | -11187.50% | -396200.00% | -373362.50% | -130.58% | 1604.05% | -95.41% | 0.07 | — | 4.57 | 4.48 | 0.23 | -1810.00% | -9529.00% | 145.00% | -16.36% | -3.08 | 1093.57% | 0.00% | 0.00% | 0.00% | -3.25 | -4.77 | 12883.26 | -2.91 |
| ACIU | AC Immune S.A. | $2.93 | 294.76M | +1,817% | -50% | — | — | -3.77 | 1.71 | 7.03 | -0.66 | — | 3.10 | -129.12% | -191.80% | -186.44% | -37.31% | -787.64% | -24.61% | 0.05 | -393.82 | 1.71 | 1.65 | 0.63 | -2031.00% | 8451.00% | -20663.00% | 34.00% | 0.65 | 981.44% | 0.00% | 0.00% | 0.00% | -0.61 | 0.49 | 1.17 | -1.52 |
| ALDX | Aldeyra Therapeutics, Inc… | $5.46 | 328.49M | — | — | — | — | 0.00 | 0.00 | — | 1.55 | — | 0.00 | 0.00% | — | — | -152.98% | 0.00% | -93.94% | 0.35 | -18.51 | 2.58 | 2.52 | 1.55 | -4043.00% | — | 7717335287.00% | -9879606.86% | -1.20 | 649.97% | 0.00% | 0.00% | 16150447.97% | 1545737.39 | 1.63 | — | -8.67 |
| CADL | Candel Therapeutics, Inc. | $5.25 | 288.22M | — | — | — | — | -4.74 | 3.94 | — | -3.31 | -14.45 | 3.94 | 0.00% | — | — | -139.56% | 293.22% | -74.53% | 0.20 | -15.97 | 2.77 | 2.74 | 1.71 | 3282.00% | — | -2208.00% | -10.33% | -0.72 | 237.58% | 0.00% | 0.00% | 29.25% | -5.17 | -6.38 | — | 1.07 |
| CLLS | Cellectis S.A. | $3.88 | 389.18M | +21,055% | +605% | — | — | -3.10 | 0.87 | 2.74 | 5.83 | — | 0.87 | 77.88% | -143.48% | -88.57% | -34.02% | 165.71% | -10.22% | 0.70 | -7.99 | 1.73 | 1.70 | 5.47 | -7684.00% | 539748.00% | -17562.00% | 17.18% | 0.13 | -54.33% | 0.00% | 0.00% | 0.12% | 0.93 | -2.83 | -1.33 | -0.96 |
| CTNM | Contineum Therapeutics, I… | $15.34 | 560.36M | +1,304% | — | — | — | -3.10 | 0.66 | — | 1.61 | — | 0.66 | 0.00% | — | — | -64.95% | 27584.82% | -24.62% | 0.03 | — | 20.69 | 20.53 | 0.37 | -34222.00% | -10000.00% | -27618.00% | -25.46% | -3.29 | 18080.76% | 0.00% | 0.00% | 147.57% | 1.33 | 2.02 | — | 4.86 |
| DRTS | Alpha Tau Medical Ltd. | $7.76 | 661.65M | — | — | — | — | -6.09 | 3.09 | — | -4.83 | -85.26 | 3.09 | 0.00% | — | — | -43.16% | -228.37% | -32.80% | 0.20 | -104.77 | 7.40 | 6.91 | 0.04 | 714.00% | — | -960.00% | -11.39% | -2.28 | -139.53% | 0.00% | 0.00% | 0.93% | -4.06 | -6.64 | — | 1.93 |
| LXEO | Lexeo Therapeutics, Inc. … | $7.18 | 524.05M | — | — | — | — | -0.87 | 0.73 | — | 0.27 | -3.62 | 0.73 | 0.00% | — | — | -85.37% | -2362.17% | -68.58% | 0.08 | -927.77 | 5.52 | 5.32 | 0.26 | 2410.00% | — | 3683.00% | -95.11% | -3.55 | -1823.16% | 0.00% | 0.00% | 0.02% | 0.24 | 0.32 | — | -2.49 |
| LYEL | Lyell Immunopharma, Inc. | $24.00 | 509.85M | -75% | -75% | — | +4,553% | -0.57 | 0.51 | 3184.91 | 0.58 | -1.41 | 0.51 | 100.00% | -588122.95% | -562285.25% | -66.10% | -295.08% | -55.28% | 0.15 | — | 7.06 | 6.89 | 0.23 | 4014.00% | -5308.00% | -212.00% | -83.83% | -3.02 | -133.95% | 0.00% | 0.00% | 0.00% | 0.33 | 0.72 | -1922.61 | -4.37 |
| MREO | Mereo BioPharma Group plc | $0.37 | 59.17M | +8,875% | — | — | — | -8.52 | 6.04 | — | -7.48 | — | 6.11 | 0.00% | — | — | -77.58% | 2839.57% | -60.54% | 0.11 | -34.56 | 5.40 | 5.28 | 1.55 | -9997.00% | -10000.00% | 5560.00% | -9.10% | -2.37 | 2010.37% | 0.00% | 0.00% | 3.23% | -6.44 | -9.09 | — | 4.76 |
| SLN | Silence Therapeutics plc | $5.44 | 256.95M | +597% | -16% | — | — | -2.07 | 0.56 | 1.73 | 1.48 | — | 0.60 | 72.70% | -146.38% | -104.74% | -46.39% | 212.32% | -22.47% | 0.00 | — | 11.14 | 10.36 | 2.47 | -3190.00% | 7047.00% | 7223.00% | -90.74% | -4.02 | 227.52% | 0.00% | 0.00% | 70.57% | 1.14 | 1.07 | -1.67 | -2.43 |
About Genelux Corporation
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
- CEO
- Thomas D. Zindrick
- Employees
- 24
- Beta
- 0.18
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $2.74) − 1 = — (DCF, example).